MAPK-IN-5

MAPK-IN-5 is a potent MAPK inhibitor with an IC50 of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer[1].

Product Specifications

CAS Number

[2579683-39-7]

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; p38 MAPK; PARP; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

COCCOC(C=C1N=CN=C2NC3=CC(C(N=N4)=CN4CC5=CC=C(C(F)(F)F)C=C5)=CC=C3)=C(C=C12)OCCOC

Molecular Formula

C30H29F3N6O4

Molecular Weight

594.58

References & Citations

[1]Wang L, et al. Design, synthesis and anti-cancer activity of novel 1,2,3-triazole hybrids of erlotinib against cervical cancer via MAPK signaling pathway. Sci Rep. 2025 Jul 9;15 (1) :24582.